Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: ARCT stock price vs DEO: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DEO's multiple
Needs DEO P/S.
Implied fair value · at ARCT's multiple
Needs ARCT P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ARCT FY 2025 (ended Dec 31, 2025) · DEO FY 2025 (ended Jun 30, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
ARCTURUS THERAPEUTICS HOLDINGS INC. · implied price per share
Bear
-$2.12
Base
-$2.50
Bull
-$2.87
DIAGEO plc · implied price per share
Bear
-$12.29
Base
-$14.46
Bull
-$16.63
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.47x
—
Net debt / EBITDA
Leverage against operating earnings
2.04x
8.42x
Cash and equivalents
Liquid reserves on the balance sheet
$230.91M
$2.20B
Total debt
Interest-bearing obligations outstanding
$101.29M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
ARCT vs MRNA
BioNTech SE
ARCT vs BNTX
ALNYLAM PHARMACEUTICALS, INC.
ARCT vs ALNY
Sarepta Therapeutics, Inc.
ARCT vs SRPT
Intellia Therapeutics, Inc.
ARCT vs NTLA
CONSTELLATION BRANDS, INC.
ARCT vs STZ
COCA COLA CO
ARCT vs KO
PEPSICO INC
ARCT vs PEP
MOLSON COORS BEVERAGE CO
ARCT vs TAP
BOSTON BEER CO INC
ARCT vs SAM
$33.20B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
